The CATIE Study
To the Editor:
The recently published CATIE study by Jeffrey A. Lieberman, M.D., et al. (1) had an immediate impact on psychiatrists and the public at large. Although thoughtful and comprehensive, the methodology of the work raises some questions concerning dosage, duration of administration, genetics, and compliance.
The authors themselves identified potential problems with the data resulting from the relatively low dosing of olanzapine, quetiapine, and ziprasidone as well as the absence of aripiprazole as a participant. Corrected data indicated that ziprasidone and olanzapine did not differ significantly with respect to efficacy or discontinuation rates. In the event of treatment failure, clozapine remained available to patients outside the study proper but was not itself included and thus precluded an important yardstick of antipsychotic action.
The late addition of ziprasidone limited its study period to less than those of the other drugs. Even so, these findings as well as earlier work militate for a more thorough evaluation of ziprasidone and the other atypical antipsychotics that merit investigation under similar conditions (2). The dose range of olanzapine exceeded the manufacturer’s recommendation (2.5–20 mg/day) by a factor of 150%, such that the mean dose, 20.8 mg/day, contrasted sharply with the other atypical medications, whose means remained substantially below their manufacturers’ recommended maxima. Perphenazine use reached its manufacturer’s suggested maximum for hospitalized patients, 32 mg/day, but not the absolute safe limit of 64 mg/day (perphenazine prescribing information from Geneva Pharmaceuticals, Inc., Broomfield, Colo.). Thus, olanzapine realized an advantage the other medications did not enjoy.
The role of genetics in schizophrenia remains largely undefined. Exclusion of patients with tardive dyskinesia from the perphenazine group may have eliminated a group of schizophrenic patients who differed genetically from the remainder. Susceptibility to tardive dyskinesia may find its explanation in polymorphisms in the dopamine D2 and D3 receptors (3).
Drug compliance among schizophrenic patients has for years plagued investigators and clinicians alike. Many other mentally ill patients, including those with bipolar disorder, also have serious compliance problems (4–8). Multiple factors affect the compliance of schizophrenic patients, including awareness of the illness, duration of the disease, insidious onset, and poor clinic attendance (9–11). Compliance may also vary with available social support, substance abuse, comorbidity, denial, and the quality of the therapeutic alliance (12–14). The causes of noncompliance are multivariant and require considerable evaluation.
Although plasma levels have not been established for ziprasidone, they have been broadly determined for the other atypical antipsychotics investigated (15, 16). Despite poor correlation with clinical response, low plasma levels have been linked to relapse, especially among those who take typical antipsychotics and remain the only indicator aside from positron emission tomography scanning, which aids in the verification of medication use (17–21). Unfortunately, the absence of plasma levels in the CATIE study means that no proof of compliance ever occurred (22).
Perphenazine use in schizophrenia has been longstanding but has not engendered wide study (23). In one comparison, investigators found the superior efficacy and safety of an atypical antipsychotic versus perphenazine (24). The rate of extrapyramidal symptoms and tardive dyskinesia differed significantly between the two drugs, with perphenazine showing increasing incidence of these side effects with time, whereas the olanzapine group showed the opposite. Why the designers of the CATIE did not choose chlorpromazine, a solidly established, thoroughly investigated benchmark, puzzles one.
The CATIE study may well overturn the impression that atypical antipsychotics outperform older antipsychotics. Still, clinicians ought not to rush to judgment but remain patient enough to await clarification of some ambiguous aspects of the study.
1. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK (Clinical Antipsychotic Trials of Intervention Effectiveness [CATIE] Investigators): Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353:1209–1223Crossref, Medline, Google Scholar
2. Bagnall A, Lewis RA, Leitner ML: Ziprasidone for schizophrenia and severe mental illness. Cochrane Database Syst Rev 2000; (4):CD001945Google Scholar
3. Chong SA, Tan EC, Tan CH, Mythily, Chan YH: Polymorphisms of dopamine receptors and tardive dyskinesia among Chinese patients with schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2003; 116:51–54Crossref, Google Scholar
4. Piette JD, Heisler M, Krein S, Kerr EA: The role of patient-physician trust in moderating medication nonadherence due to cost pressures. Arch Intern Med 2005; 165:1749–1755Crossref, Medline, Google Scholar
5. Day D: AIP: a proposed mechanism for evaluating adherence improvement initiatives. Adv Ther 2005; 22:87–95Crossref, Medline, Google Scholar
6. Valdez CA, Ulrich H: Similar medication compliance and control of dyslipidemia with simvastatin or atorvastatin in a staff-model HMO medical clinic. J Manag Care Pharm 2005; 11:499–504Medline, Google Scholar
7. Yiannakopoulou ECh, Papadopulos JS, Cokkinos DV, Mountokalakis TD: Adherence to antihypertensive treatment: a critical factor for blood pressure control. Eur J Cardiovasc Prev Rehabil 2005; 12:243–249Crossref, Medline, Google Scholar
8. Scott J, Pope M: Nonadherence with mood stabilizers: prevalence and predictors. J Clin Psychiatry 2002; 63:384–390Crossref, Medline, Google Scholar
9. Smith CM, Barzman D, Pristach CA: Effect of patient and family insight on compliance of schizophrenic patients. J Clin Pharmacol 1997; 37:147–154Crossref, Medline, Google Scholar
10. Amadio PB, Cross LB, Amadio P Jr: New drugs for schizophrenia: an update for family physicians. Am Fam Physician 1997; 56:1149-1156, 1159-1160; correction, 1998; 57:40Google Scholar
11. Chabannes JP, Benattia I, Pascal JC, Azorin JM, Vidon G, Bouhassira M, Allicar MP: [What is the meaning of “stabilization” in schizophrenic patients?] Encephale 1998; 24:331–336 (French)Medline, Google Scholar
12. Conley RR, Buchanan RW: Evaluation of treatment-resistant schizophrenia. Schizophr Bull 1997; 23:663–674Crossref, Medline, Google Scholar
13. Chronic ambulatory outpatients and four-vector management. Am J Manag Care 1998; 4(suppl):S15-S19Google Scholar
14. Garavan J, Browne S, Gervin M, Lane A, Larkin C, O’Callaghan E: Compliance with neuroleptic medication in outpatients with schizophrenia: relationship to subjective response to neuroleptics; attitudes to medication and insight. Compr Psychiatry 1998; 39:215–219Crossref, Medline, Google Scholar
15. Hiemke C, Dragicevic A, Grunder G, Hatter S, Sachse J, Vernaleken I, Muller MJ: Therapeutic monitoring of new antipsychotic drugs. Ther Drug Monit 2004; 26:156–160Crossref, Medline, Google Scholar
16. Midha KK, Hubbard JW, Marder SR, Marshall BD, Van Putten T: Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia. J Psychiatry Neurosci 1994; 19:254–264Medline, Google Scholar
17. Seeman P: Atypical antipsychotics: mechanism of action. Can J Psychiatry 2002; 47:27–38Medline, Google Scholar
18. Ulrich S, Baumann B, Wolf R, Lehmann D, Peters B, Bogerts B, Meyer FP: Therapeutic drug monitoring of clozapine and relapse—a retrospective study of routine clinical data. Int J Clin Pharmacol Ther 2003; 41:3–13Crossref, Medline, Google Scholar
19. Raggi MA: Therapeutic drug monitoring: chemical-clinical correlations of atypical antipsychotic drugs. Curr Med Chem 2002; 9:1397–1409Crossref, Medline, Google Scholar
20. Rao ML, Hiemke C, Grasmader K, Baumann P (TDM Arbeitsgruppe Der AGNP): [Olanzapine: pharmacology, pharmacokinetics and therapeutic drug monitoring.] Fortschr Neurol Psychiatr 2001; 69:510–517 (German)Crossref, Medline, Google Scholar
21. Hiemke C, Dragicevic A, Grunder G, Hatter S, Sachse J, Vernaleken I, Muller MJ: Therapeutic monitoring of new antipsychotic drugs. Ther Drug Monit 2004; 26:156–160Crossref, Medline, Google Scholar
22. Miller RS, Peterson GM, McLean S, Westhead TT, Gillies P: Monitoring plasma levels of fluphenazine during chronic therapy with fluphenazine decanoate. J Clin Pharm Ther 1995; 20:55–62Crossref, Medline, Google Scholar
23. Hartung B, Wada M, Laux G, Leucht S: Perphenazine for schizophrenia. Cochrane Database Syst Rev 2005; (1):CD003443Google Scholar
24. Jarema M, Olajossy M, Chrzanowski W, Araszkiewicz A, Landowski J, Rybakowski J, Bilikiewicz A, Bomba J, Debowska G: [Safety and efficacy of olanzapine versus perphenazine in patients with schizophrenia: results of multicenter, 18-week, double-blind clinical trial]. Psychiatr Pol 2003; 37:641–655 (Polish)Medline, Google Scholar
